Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
Holding TVTX?
Track your performance easily
TVTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.12 - $13.97
Previous Close$13.48
Volume3.74M
Average Volume (3M)1.33M
Market Cap
$1.09B
Enterprise Value$1.11B
Total Cash (Recent Filing)$325.40M
Total Debt (Recent Filing)$403.23M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Nov 06, 2024EPS Estimate
-$0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.84
Shares Outstanding76,491,485
10 Day Avg. Volume2,739,973
30 Day Avg. Volume1,331,556
Standard Deviation0.17
R-Squared0.05
Alpha0.00019
Financial Highlights & Ratios
Price to Book (P/B)71.35
Price to Sales (P/S)5.80
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.24
Enterprise Value/Gross Profit8.29
Enterprise Value/Ebitda-5.82
Forecast
1Y Price Target
$18.08Price Target Upside26.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Travere Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical ValidationFILSPARI significantly slowed kidney function decline over two years compared to active control ARB, irbesartan, thereby confirming and validating the initial approval and the overall PROTECT study.
FDA ApprovalThe full approval and updated drug label, together with the inclusion of Filspari into the Guidelines, generates a strong opportunity for an additional increase in sales revenue.
Market ExpansionRemoving the proteinuria threshold is critical, as it nearly doubles the TAM of FILSPARI for IgAN in the U.S. to over 70,000 patients, from 30,000-50,000 previously.
Bears Say
Clinical Trial ResultsTravere Therapeutics (TVTX) shares continue to trade below last years’ levels after the 2-year PROTECT data disappointed.
Regulatory SupportSupport to reduce REMS remains but likely to take time.
Stock PerformanceShares of Travere are down ~66% since the Accelerated Approval of Filspari in February 2023.
---
Ownership Overview
7.99% Insiders
26.86% Mutual Funds
65.12% Other Institutional Investors
0.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TVTX FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Travere Therapeutics lowest stock price was $5.12 and its highest was $13.97 in the past 12 months.
What is Travere Therapeutics’s market cap?
Currently, no data Available
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on Aug 01, 2024. The company reported -$0.91 earnings per share for the quarter, missing the consensus estimate of -$0.791 by -$0.119.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is -$0.63.
How many shares outstanding does Travere Therapeutics have?
Travere Therapeutics has 76,491,486 shares outstanding.
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of -$0.91 in its last earnings report, missing expectations of -$0.791. Following the earnings report the stock price went down -2.597%.
Which hedge fund is a major shareholder of Travere Therapeutics?
Among the largest hedge funds holding Travere Therapeutics’s share is Woodline Partners LP. It holds Travere Therapeutics’s shares valued at 10M.
---
Travere Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.08 (26.70% Upside)
$18.08 (26.70% Upside)
Blogger Sentiment
Bearish
TVTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 20.6%
Last 30 Days ▲ 20.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.88%
12-Months-Change
Fundamentals
Return on Equity
-582.60%
Trailing 12-Months
Asset Growth
-25.16%
Trailing 12-Months
Company Description
Travere Therapeutics
Travere Therapeutics is focused on developing therapies for rare kidney and metabolic disorders. The biopharmaceutical company's products include FILSPARI (sparsentan), and Thiola and Thiola EC (tiopronin tablets).
---
TVTX Earnings Call
Q2 2024
0:00 / 0:00
---
TVTX Stock 12 Month Forecast
Average Price Target
$18.08
▲(26.70% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Seres Therapeutics
―
Xeris Pharmaceuticals
―
Arvinas Holding Company
―
Best Analysts Covering TVTX
1 Year
1 Year Success Rate
14/23 ratings generated profit
1 Year Average Return
+11.16%
assigned a buy rating 14 days ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 60.87% of your transactions generating a profit, with an average return of +11.16% per trade.
---